Keros Therapeutics (KROS) Revenue (2019 - 2025)
Keros Therapeutics' (KROS) quarterly Revenue came in at $188000.0 in Q4 2025, down 93.82% YoY from $3.0 million in Q4 2024, and down 98.67% on a QoQ basis from $14.1 million in Q3 2025.
Keros Therapeutics (KROS) Revenue (2019 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 6 years of Revenue data on file, last reported at $188000.0 in Q4 2025.
- Quarterly Revenue fell 93.82% year-over-year to $188000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $243.7 million (up 6837.83% YoY) and the FY2025 annual result came in at $243.9 million, up 6769.41% from the prior year.
- Revenue eased to $188000.0 in Q4 2025, from $14.1 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $211.2 million in Q1 2025 to a low of $8000.0 in Q3 2023.
- A 5-year average of $23.6 million and a median of $1.7 million in 2024 frame the typical range for Revenue.
- The widest YoY moves for Revenue: up 254413.25% in 2025, down 93.82% in 2025.
- Tracing KROS's Revenue over 5 years: stood at $17.9 million in 2021, then grew by 0.56% to $18.0 million in 2022, then slumped by 99.21% to $143000.0 in 2023, then jumped by 2027.27% to $3.0 million in 2024, then plunged by 93.82% to $188000.0 in 2025.
- The last three Revenue figures came in at $188000.0 (Q4 2025), $14.1 million (Q3 2025), and $18.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 1.29 Bn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | 1.06 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 425.49 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 674.14 Mn |
| 10 | Keros Therapeutics | 216.12 Mn | -41.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 188,000.00 |
| Sep 30, 2025 | 14.12 Mn |
| Jun 30, 2025 | 18.17 Mn |
| Mar 31, 2025 | 211.25 Mn |
| Dec 31, 2024 | 3.04 Mn |
| Sep 30, 2024 | 388,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Dec 31, 2023 | 143,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Mar 31, 2022 | 18.00 Mn |
| Dec 31, 2021 | 17.90 Mn |
| Jun 30, 2021 | 100,000.00 |
| Dec 31, 2019 | 2.50 Mn |
| Sep 30, 2019 | 2.50 Mn |
| Jun 30, 2019 | 2.50 Mn |
| Mar 31, 2019 | 2.50 Mn |